Delphi advises Hamlet Pharma in merger with SelectImmune

Delphi has advised the listed company Hamlet Pharma AB (publ) in a proposed merger with the listed company SelectImmune Pharma AB (publ). Through the merger of the companies, “Hamlet Biopharma” will be established with the aim of becoming a powerful pharmaceutical company for the development of drugs for the treatment of cancer and infectious diseases.

Delphi’s team consisted of Mats Dahlberg, Jenny Lindén, Emilia Hjers and Dahae Roland.